Guggenheim lowered the firm’s price target on Krystal Biotech (KRYS) to $189 from $195 and keeps a Buy rating on the shares. $88M in Vyjuvek sales “handily missed” the $96.8M consensus and without a clear outlook on new patient adds and compliance, the next couple of quarters are “challenging” until the company gets traction in the EU and Japan, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech: Buy Rating Amid Temporary Revenue Dip and Promising Growth Prospects
- Krystal Biotech Reports Strong Q1 2025 Results
- Krystal Biotech’s Earnings Call Highlights Growth and Expansion
- Krystal Biotech’s Growth Potential: Addressing Challenges with Strategic Initiatives and Strong Market Presence
- Krystal Biotech’s Long-Term Growth Potential Amid Short-Term Challenges: A Buy Rating by Sami Corwin